Proteon Therapeutics (PRTO) Earning Somewhat Positive Media Coverage, Analysis Shows
News stories about Proteon Therapeutics (NASDAQ:PRTO) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Proteon Therapeutics earned a daily sentiment score of 0.00 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 44.5994409388709 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
A number of research firms have weighed in on PRTO. HC Wainwright restated a “hold” rating and set a $2.30 price objective on shares of Proteon Therapeutics in a research report on Wednesday, November 8th. Zacks Investment Research cut shares of Proteon Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 18th. Finally, Robert W. Baird restated a “hold” rating and set a $2.00 price objective on shares of Proteon Therapeutics in a research report on Friday, November 10th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $3.20.
Shares of Proteon Therapeutics (NASDAQ PRTO) traded up $0.05 during midday trading on Monday, hitting $1.90. 27,600 shares of the stock were exchanged, compared to its average volume of 105,482. The firm has a market capitalization of $34.38, a PE ratio of -0.86 and a beta of 1.62. Proteon Therapeutics has a 1-year low of $1.10 and a 1-year high of $2.75.
In other Proteon Therapeutics news, Director James E. Flynn bought 110,557 shares of Proteon Therapeutics stock in a transaction dated Thursday, November 30th. The stock was acquired at an average cost of $1.75 per share, for a total transaction of $193,474.75. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders bought 122,852 shares of company stock valued at $216,533 over the last quarter. Company insiders own 36.30% of the company’s stock.
About Proteon Therapeutics
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.